Friday, August 19, 2011
I'm on my blogging break, but I just received some exciting news and had to post. Today, the FDA gave accelerated approval for Seattle Genetic's ADCESTRIS for the treatment of Hodgkin's Lymphoma in patients that relapse after an autologous stem cell transplant.
Right now Reid is participating in their clinical trial, but for people that aren't in a trial and relapse this will give them access to the drug too. Over the years there hasn't been a lot of research done since Hodgkin's is a rare cancer with a normally high cure rate. It's when people relapse that the options are limited and this is a cancer that effects mostly young people. It's my understanding that this is the first new drug since the 1970's that's been approved for Hodgkin's Lymphoma.
Thank you Seattle Genetics.